Commentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling
|
|
|
- Scot Day
- 9 years ago
- Views:
Transcription
1 Commentary USP 36-NF 31 Excerpt Related to General Chapter <17> Prescription Container Labeling In accordance with USP s Rules and Procedures of the Council of Experts ( Rules ), USP publishes all proposed revisions to the United States Pharmacopeia and the National Formulary (USP-NF) for public review and comment in the Pharmacopeial Forum (PF), USP s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be republished in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without republication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP Web site at the time the official revision is published 1. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia Twinbrook Parkway Rockville, MD USA [email protected] General Chapter/Section(s): General Chapter <17> Prescription Container Labeling Expert Committee(s): Nomenclature, Safety and Labeling No. of Commenters: 193 Introduction and General Comments Comment Summary #1: Several commenters suggested that responsibility and oversight be assigned for creation and maintenance of standardized formats, dictionaries, and glossaries. 1 The Commentary for General Chapter <17> Prescription Container Labeling is being posted early to correspond with the early posting of the final General Chapter.
2 Response: Comment not incorporated. The jurisdiction of prescription container labeling is state by state and thus may vary. Comment Summary #2: Several commenters indicated that compressed gas is exempted from prescription container labeling according to 21CFR and should also be exempt from the standard. Comment Summary #3: Several commenters suggested that specific technologies be applied to manage the patient centered label. Response: Comment not incorporated. The Expert Committee does not endorse any particular type of technology to allow for flexibility and cost considerations to accomplish compliance with the standards. Comment Summary #4: Several commenters suggested that the General Chapter emphasize that the standards pertain to prescription containers that are directly dispensed to patients. Comment Summary #5: Several commenters suggested that the label specifications in the standards be compliant with federal and state laws. Comment Summary #6: Several commenters suggested the patient has the right to know the country of origin of the drug. Response: Comment not incorporated. This is a supply chain issue and will be considered for incorporation in the General Chapter related to supply chain management. Comment Summary #7: Several commenters suggested that the brand name and the generic name be included on the prescription container label. Comment Summary #8: A commenter suggested that the written medication description and picture be required on the prescription container label. Response: Comment not incorporated. The General Chapter allows for flexibility in the manner in which a patient centered label can be accomplished but does not require a written medication description or picture. Comment Summary #9: A commenter suggested that the use of standardized color and shape be required on the patient centered label to identify medication. Response: Comment not incorporated. The General Chapter allows for flexibility in the manner in which a patient centered label can be accomplished but does not require the use of color or shape. Comment Summary #10: A commenter suggested that the General Chapter be numbered over 1000 to be considered as a voluntary guideline rather than an enforceable chapter (numbered below 1000). Response: Comment not incorporated. The root cause for patient misunderstanding, non-adherence, and medication errors is a lack of universal standards for labeling on dispensed prescription containers. The standard will be more readily adopted by state regulatory agencies if the chapter is numbered below Comment Summary #11: A commenter suggested that the gluten status of the medication be included on the prescription container label.
3 Response: Comment not incorporated. There are currently no standards related to gluten content in drugs. Comment Summary #12: Several commenters suggested that the General Chapter be eliminated due to unjust financial impact to vendors, pharmacies, and patients. Response: Comment not incorporated. The prescription container labeling standards were developed to promote patient understanding and prevent medication misuse, nonadherance, and medication errors. Organize Prescription Label in Patient Centered Manner Comment Summary #1: A commenter suggested that the organization of the label not be specified. Response: Comment not incorporated. Information shall be organized in a way that best reflects how most patients seek out and understand medication instructions. Comment Summary #2: One commenter suggested that the patient centered label be field tested. Response: Comment not incorporated. Two states have adopted patient centered labels that were reviewed by the Expert Committee. Comment Summary #3: Several commenters suggested that examples of patient centered labels be incorporated in the General Chapter. manner in which the patient center label can be accomplished. Emphasize Instructions to Patients Comment Summary #1: Several commenters suggested prescriber contact information be included as critically important information. Response: Comment not incorporated. The Expert Committee acknowledges the importance of prescriber contact information but this should not supersede information critical to the patient s safe and effective use of the medicine. Comment Summary #2: A commenter suggested that the medication picture be required on the patient centered label. Response: Comment not incorporated. The General Chapter allows for flexibility in the Simplify Language Comment Summary #1: Several commenters suggested that SIG be defined. Comment Summary #2: Several commenters suggested that the SIGs (signature, directions) be standardized. Response: Comment not incorporated. The Expert Committee agrees standard directions should be used whenever possible but standardizing the SIG did not fall within the scope of this revision. The Expert Committee will review further studies. Give Explicit Instructions Comment Summary #1: A commenter suggested that the principles of Doak, Doak be defined.
4 Response: Comment not incorporated. Doak, Doak and Root reference were removed and replaced with other health literacy references that are more accessible. Comment Summary #2: A commenter suggested that a direction schema be developed and incorporated into the prescription container label standards. Response: Comment not incorporated. There is continuing research in this area. Best practices will be considered for future revisions as evidence becomes available. Comment Summary #3: Several commenters suggested that the instructions should take into account a patient s lifestyle, e.g., different shift work hours. The Expert Committee acknowledges that dosing by precise hours may present greater adherence issues due to individual lifestyle patterns and general time frames such as in the morning may be more easily understood. Include Purpose for Use Comment Summary #1: Several commenters suggested that Include Purpose for Use not be required in the standard. Response: Comment not incorporated. The Expert Committee decided that if the purpose of the medication is included on the prescription, then it should be included on the prescription container label. Comment Summary #2: Several commenters suggested that the prescriber be required to write the purpose for use on the prescription. Response: Comment not incorporated. The General Chapter does not address how a prescription should be written. Comment Summary #3: Several commenters suggested that patient preference for inclusion of the purpose for use be excluded. Response: Comment not incorporated. The label is meant to be patient-centered to allow for patient preference. Comment Summary #4: A commenter suggested that prescription container labeling should include contraindications, side effects, interactions with other medications, directions for use and the drug s purpose for use as approved by the Food and Drug Administration (FDA). Response: Comment not incorporated. The Expert Committee decided that if the FDA-approved purpose of the medication is included on the prescription, then it should be included on the prescription container label. The prescription container label should feature only the most important patient information needed for safe and effective understanding and use. Less critical but important content should be placed away from dosing instructions because it distracts patients, and this can impair patients recognition and understanding. Medication guides that accompany the prescription are still appropriate for elements such as FDA approved use, contraindications, side effects, and drug interactions. Limit Auxiliary Information Comment Summary #1: A commenter suggested getting patient feedback (which is important to the patient) should be included on the auxiliary information.
5 Response: Comment not incorporated. The General Chapter recommends getting patient feedback on simplified language on the patient-centered label. If the auxiliary information is printed on the label, the standard would apply. Comment Summary #2: One commenter suggested adding pregnancy and lactation status of the drug product with accompanying side effects, contraindications and interactions. Response: Comment not incorporated. The items requested are beyond the scope of the prescription container label and would be listed in the medication guide given with the prescription at time of dispensing. Comment Summary #3: Several commenters suggested that a clear statement referring the patient to supplemental instructions be stated on the label. Address Limited English Proficiency Comment Summary #1: Several commenters suggested that the label specifications address patients with low English proficiency. Comment Summary #2: Several commenters suggested that the label be produced in a language that the patient understands. Response: Comment not incorporated. Whenever possible, the directions for use should be provided in the patient s preferred language. Improve Readability Comment Summary #1: A commenter suggested that a minimum font size be included for non-critical information. Comment Summary #2: Several commenters suggested that the font on the entire label be 12 pt. Response: Comment not incorporated. 12 pt font size (New Times Roman) or 11 pt Arial are to be used for critical information. Comment Summary #3: Several commenters suggested that the use of 12 pt font would result in the use of larger labels and containers. Comment Summary #4: A commenter suggested that a statement be included to provide adequate space between words and numerals. Response: Comment not incorporated. The typography of the label shall be optimized to include white space to distinguish sections on the label, but does not require a statement to provide adequate space between words and numerals. Comment Summary #5: A commenter suggested the use of two labels on prescription containers. Response: Comment not incorporated. The General Chapter allows for flexibility in the Comment Summary #6: A commenter suggested a standardized location on the prescription label for prescription date and beyond use date.
6 Response: Comment not incorporated. The General Chapter allows for flexibility in the Comment Summary #7: Several commenters suggested that the prescription container labeling address access for the visually impaired. Comment Summary #8: A commenter suggested that the lot number and or expiration date be standard information on the label. Comment Summary #9: A commenter suggested that the barcode be required as standard information on the label. Barcode technology currently is not universally available in all practice settings. Comment Summary #10: A commenter suggested that while the specific hour for dosing emphasizes patient understanding, it is not within the realm of pharmacy practice to convert or interpret the prescription. Response: Comment not incorporated. The General Chapter states, whenever available, use standardized directions and recognizes that regulations and authoritative bodies will determine how the standards will be adopted Comment Summary #11: A commenter suggested the General Chapter highlight further research being done to test proposed changes. Response: Comment not incorporated. The General Chapter is dynamic and will incorporate evidence based information in future revisions if warranted.
Health Literacy & Medication Safety
Health Literacy & Medication Safety Can We Confuse Patients Less? Michael S. Wolf, MA MPH PhD Assistant Professor and Director Health Literacy and Learning Program (HeLP) Division of General Internal Medicine
Guidance for Industry
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013
Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR S OFFICE PHARMACY PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION DRUGS (By authority conferred on the director of the department of licensing and
How To Understand The Benefits Of Electronic Prescribing
B A R B A R A J. L I M A N D R I, D N S C, A P R N, B C L I N F I E L D C O L L E G E P O R T L A N D D I A L E C T I C A L B E H A V I O R T H E R A P Y P R O G R A M LEARNING OUTCOMES By the completion
Standards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
QUALIFICATION DETAILS
QUALIFICATION DETAILS Qualification Title New Zealand Certificate in Pharmacy (Pharmacy Technician) (Level 4) Version 1 Qualification type Certificate Level 4 Credits 75 NZSCED DAS Classification Strategic
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
105 CMR: DEPARTMENT OF PUBLIC HEALTH 105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS
105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS Section 210.001: Purpose 210.002: Definitions 210.003: Policies Governing the Administration of Prescription
THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234
THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: The Professional Practice Committee Douglas E. Lentivech SUBJECT: Proposed Amendment of the Regulations
ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS
ALABAMA BOARD OF NURSING ADMINISTRATIVE CODE CHAPTER 610-X-5 ADVANCED PRACTICE NURSING COLLABORATIVE PRACTICE TABLE OF CONTENTS 610-X-5-.01 610-X-5-.02 610-X-5-.03 610-X-5-.04 610-X-5-.05 610-X-5-.06 610-X-5-.07
Guidelines on Counseling. Approved by PEIPB
Guidelines on Counseling Approved by PEIPB November 2005 1 Patient Counseling Patient counseling is a key competency element of the Pharmaceutical Care process. Given the advertising for medication in
AATB/ICCBBA Interim Guidance Document. For use of ISBT 128 by North American Tissue Banks
AATB/ICCBBA Interim Guidance Document For use of ISBT 128 by North American Tissue Banks Version 1.2.0 September 2012 Published by: ICCBBA PO Box 11309, San Bernardino, California, USA 1.909.793.6516 [email protected]
ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS
Medical Examiners Chapter 540-X-8 ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-8 ADVANCED PRACTICE NURSES: COLLABORATIVE PRACTICE TABLE OF CONTENTS 540-X-8-.01 540-X-8-.02 540-X-8-.03
Veterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
A safe return and reuse protocol in the community pharmacy setting may include, but is not limited to, the following elements:
National Association of Boards of Pharmacy Position Statement on the Return and Reuse of Prescription Medications in the Community Pharmacy Setting July 2009 The National Association of Boards of Pharmacy
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
Ambulatory Surgical Centers Frequently Asked Questions
Ambulatory Surgical Centers Frequently Asked Questions Index Top General Definitions Compliance with State Licensure Laws Governing Body and Management Surgical Services Quality Assessment and Performance
ADMINISTRATION OF MEDICATIONS POLICY
Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including
Administrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs
Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health
The United States Pharmacopeia
INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
Guidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Guidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
Guidance. Useful Written Consumer Medication Information (CMI)
Guidance Useful Written Consumer Medication Information (CMI) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
Eight Important Principles For Managing Prescription Medications In the Athletic Training Room
Eight Important Principles For Managing Prescription Medications In the Athletic Training Room Robert Nickell, RPh, FAPO, FCPHA, FACA Sports Pharmacist USA Team Pharmacist President and CEO, Sportpharm
Welcome to OptumRx Your Prescription Benefit Program
Welcome to OptumRx Your Prescription Benefit Program OptumRx offers you more ways to improve your health, while keeping medications more affordable and accessible. Welcome to OptumRx OptumRx manages your
A competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
Analysis of Various Vitamins in Multivitamin Tablets
High Performance Liquid Chromatography Analysis of Various Vitamins in Multivitamin Tablets Effective August 24, 2007, the US Food and Drug Administration (FDA) issued a regulation (21 CFR Part 111) that
8. A listing of the medications that are approved for use within a system is a/an A) inventory. B) wholesaler. C) database. D) formulary.
Name: Date: 1. A pharmacy technician searching for standards of practice regarding compounding sterile and non-sterile products would consult which reference book? A) King's Guide to Parenteral Admixtures
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
PRINCIPLES OF PHARMACOLOGY. MEDICAL ASSISTANT S ROLE History: Drug Legislation & Regulation. Education: indication, instructions, side effects
PRINCIPLES OF PHARMACOLOGY Medical Assistants At the heart of health care MEDICAL ASSISTANT S ROLE History: prescription over the counter (OTC) alcohol (ETOH), recreational, smoking, herbal remedies Education:
Guidance for Industry
Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food
From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts
RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:
HEALTH REQUIREMENTS & SERVICES: MEDICAL TREATMENT
DESCRIPTOR TERM: Students Millard District Policy File Code: 6200 1 st Reading: 05-08-14 HEALTH REQUIREMENTS & SERVICES: MEDICAL TREATMENT Purpose The purpose of this policy is to authorize school personnel
247 CMR: BOARD OF REGISTRATION IN PHARMACY
247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,
NH Laws / Rules Regarding Limited Retail Drug Distributors
NH Laws / Rules Regarding Limited Retail Drug Distributors 318:1, VII-a. "Limited retail drug distributor'' means a distributor of legend devices or medical gases delivered directly to the consumer pursuant
A b i l e n e I n d e p e n d e n t S c h o o l D i s t r i c t ABILENE INDEPENDENT SCHOOL DISTRICT MEDICATION ADMINISTRATION PROCEDURES
A b i l e n e I n d e p e n d e n t S c h o o l D i s t r i c t 241 Pine Street Abilene, Texas 79601 (325) 677-1444 ABILENE INDEPENDENT SCHOOL DISTRICT MEDICATION ADMINISTRATION PROCEDURES All prescription
Philosophy: Although sample medication may be helpful in patient care, drug samples:
Title: Policy on Sample Medication Policy #: 450.80 Adopted: 1/90, 7/00 Revised: 3/95, 5/98, 7/00, 10/01 Reviewed: 7/00, 10/01, 02/03 This policy is applicable to the following Henry Ford Health System
MAPD-SNP Contract Numbers: H5852; H3132
Policy and Procedure No: 93608 PHP Transition Process Title: Part D Transition Process Department: Pharmacy Services, Managed Care Effective Date: 1/1/2006 Supercedes Policy No: PH 8.0 Reviewed/Revised
American Academy of Physician Assistants
950 North Washington Street Alexandria, VA 22314-1552 703/836-2272 Fax 703/684-1924 TESTIMONY OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS SUBMITTED TO THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TASK
Purpose... 2. What s new?... 2. Role of pharmacists and pharmacy technicians in physician-assisted death... 3
Table of Contents Purpose... 2 What s new?... 2 Role of pharmacists and pharmacy technicians in physician-assisted death... 3 Complying with ACP s Standards of Practice for Pharmacists and Pharmacy Technicians...
Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO
Development and Validation of In Vitro Diagnostic Tests YC Lee, Ph.D. CEO 1 Validation of In Vitro Diagnostic Tests Validated d Diagnostic Test should: Provides test results that identify if positive i
Breakout Sessions: FDA s Regulation of Mobile Health and Medical Applications
Breakout Sessions: FDA s Regulation of Mobile Health and Medical Applications 2015 Annual Conference Washington, DC Bakul Patel, Associate Director for Digital Health, Office of Center Director, Center
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
Supplement to the Guidance for Electronic Data Capture in Clinical Trials
Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this
Evaluating the impact of REMS on burden and patient access
Evaluating the impact of REMS on burden and patient access Doris Auth, Pharm.D. Team Leader, Division of Risk Management Office of Medication Error Prevention and Risk Management Center for Drug Evaluation
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
Chapter. History and Traditional Technician Roles
Chapter 1 History and Traditional Technician Roles 1 9781449629823_CH01_001_014.indd 1 2 History and Traditional Technician Roles Case Study for Discussion Would it be helpful if pharmacists and pharmacy
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
Formulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
How To Prevent Medication Errors
The Academy of Managed Care Pharmacy s Concepts in Managed Care Pharmacy Medication Errors Medication errors are among the most common medical errors, harming at least 1.5 million people every year. The
NCPDP Electronic Prescribing Standards
NCPDP Electronic Prescribing Standards September 2014 1 What is NCPDP? An ANSI-accredited standards development organization. Provides a forum and marketplace for a diverse membership focused on health
Report of the Task Force on Drug Return and Reuse Programs
Report of the Task Force on Drug Return and Reuse Programs Members Present: Ron Klein (VT), chair; Lois Anderson (LA); Phil Burgess (IL); Trish D Antonio (DC); Benjamin Fry (TX); Bob Goetz (MN); Suzan
Abacus Rx, Inc. 8000 SW 117 Ave PH-G Visit us at Miami, FL 33183 (305) 220-0400 Fax (305) 220-4900
Abacus Rx, Inc. 8000 SW 117 Ave PH-G Visit us at Miami, FL 33183 (305) 220-0400 Fax (305) 220-4900 www.abacusrx.com Thank you for your inquire! We are committed to provide Pharmacies with the finest technology
How To Help The Global Healthcare User Group (Hug)
HUG Global Healthcare User Group - HUG GS1 s Brand Architecture 2 The global Healthcare User Group - HUG Mission: Lead the healthcare industry to the effective utilization and development of global standards
Pharmacy Handbook. Understanding Your Prescription Benefit
Pharmacy Handbook Understanding Your Prescription Benefit 1 Welcome to Your Prescription Drug Plan! Health Republic Insurance of New York has partnered with US Script to manage your prescription drug benefits.
Accredited Checking Technician (ACT) Standard Operating Procedures
Accredited Checking Technician (ACT) Standard Operating Procedures Standard Operating Procedures (SOP) 09/07 Standard Operating Procedures: For use in a pharmacy with an ACT (Accredited Checking Technician)
A Stability Program for the Distribution of Drug Products
A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained
UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money
UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money HEALTH NET MAKES USING YOUR NEW PHARMACY PLAN TROUBLE-FREE
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance
Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Martin s Point Generations Advantage Policy and Procedure Form
SCOPE: Martin s Point Generations Advantage Policy and Procedure Form Policy #: PartD.923 Effective Date: 4/16/10 Policy Title: Part D Transition Policy Section of Manual: Medicare Prescription Drug Benefit
Guidance for Industry
Guidance for Industry Labeling for Human Prescription Drug and Biological Products Implementing the PLR Content and Format Requirements U.S. Department of Health and Human Services Food and Drug Administration
Open Microphone Meeting:
Open Microphone Meeting: USP General Chapter Pharmaceutical Compounding Sterile Preparations October 21, 2015 2:00 p.m. to 4:00 p.m. EDT Agenda Welcome Overview of USP s Revision Process Overview
02- DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION. Chapter 8 REGULATIONS RELATING TO ADVANCED PRACTICE REGISTERED NURSING
02- DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 380 BOARD OF NURSING Chapter 8 REGULATIONS RELATING TO ADVANCED PRACTICE REGISTERED NURSING SUMMARY: This chapter identifies the role of a registered
Understanding Alberta s Drug Schedules
Understanding Alberta s Drug Schedules Preface In May 2002, the provincial drug schedules to the Pharmaceutical Profession Act were amended. In April 2007, the Alberta Regulation 66/2007 to the Pharmacy
- 1 - First Time Pharmacy Managers (Revised 02/02/2011)
State of Connecticut Department of Consumer Protection Commission of Pharmacy 165 Capitol Avenue, Room 147 Hartford, CT 06106 - Telephone: 860-713-6070 ALL FIRST-TIME PHARMACY MANAGERS ARE REQUIRED TO
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Application Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
Generic and Brand Name Drugs: Understanding the Basics
Generic and Brand Name Drugs: Understanding the Basics We ve been there. We can help. Joe has just been diagnosed with bipolar disorder. After talking to his doctor, he decides to see a therapist and go
Information Governance and Management Standards for the Health Identifiers Operator in Ireland
Information Governance and Management Standards for the Health Identifiers Operator in Ireland 30 July 2015 About the The (the Authority or HIQA) is the independent Authority established to drive high
Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps
Guidance for Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Time Stamps Draft Guidance This guidance document is being distributed for comment purposes only. Comments and suggestions
SECTION.1800 - PRESCRIPTIONS
SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or
Guidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
California E-Pedigree Update. August 2013
California E-Pedigree Update August 2013 1 Virginia Herold Executive Officer California State Board of Pharmacy www.pharmacy.ca.gov [email protected] 2 2 Statutory Mandate Protection of the public
THE VALSPAR CORPORATION
THE VALSPAR CORPORATION LABELING REQUIREMENTS FOR RAW MATERIALS SENT TO ALL VALSPAR CORPORATION LOCATIONS IN NORTH AMERICA January 2004 TABLE OF CONTENTS 1 Introduction...4 2 Compliance...4 3 Rationale...4
Medication Safety Committee Guidelines. Emergency Department Medication Management Safety Tool
ication Safety Committee Guidelines Department ication Management Safety Tool TABLE OF CONTENTS REVISION LOG... 2 INTRODUCTION... 3 COMMITTEE REPRESENTATION... 3 EMERGENCY DEPARTMENT MEDICATION MANAGEMENT
Policy on the Appropriate Use of Telemedicine Technologies in the Practice of Medicine
Background and Introduction The Vermont Board of Medical Practice (the Board) is committed to protecting the public and to assisting its licensees to meet their professional obligations by providing quality
UW School of Dentistry Comprehensive Medication Policy
UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides
The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies.
1 NABP Model State Pharmacy Act & Model Rules Appendix B Good Compounding Practices Applicable to State Licensed Pharmacies The following Good Compounding Practices (GCPs) are meant to apply only to the
TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Initial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS) Page 1 of 16 I. GOALS The goals of the TIRF
1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY
BRIEFING 1083.4 Supply Chain Integrity and Security. A new series of general informational chapters describing various aspects of the pharmaceutical supply chain replaces Good Distribution Practices Supply
